Senhwa Biosciences, Inc. is a Taiwan-based company principally engaged in the research and development of anti-cancer new drugs and special drug substances. The Company's main development projects include the CX-5461, for the treatment of hematologic cancers and breast cancers, as well as the CX-4945, for the treatment of cholangiocarcinoma. The Company has not generated any revenues yet.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-10-30	NT$30.95	-2.52%	323,482
26-10-29	NT$31.75	-1.24%	70,765
26-10-28	NT$32.15	-0.31%	76,005
26-10-27	NT$32.25	-0.77%	125,673

End-of-day quote Taipei Exchange

More quotes

End-of-day quote Taipei Exchange 2026-10-30			5-day change	1st Jan Change
30.95 ^TWD	-2.52%		-4.77%	-29.66%

08-25	Senhwa Biosciences Completes Enrollment in Phase 1B Cx-5461 Expansion Trial	CI
08-13	Senhwa Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Market Cap	2.77B 84.85M 75.95M 69.91M 63.28M 118M 8.06B 121M 833M 333M 4.23B 318M 312M 13.37B	P/E 2024	-13.2x	P/E 2025	-14.8x
Enterprise Value	2.02B 61.86M 55.37M 50.97M 46.13M 86.32M 5.87B 88.01M 607M 243M 3.09B 232M 227M 9.74B	EV / Sales 2024	2,869x	EV / Sales 2025	2,967x
Free-Float	80.87%	Yield 2024 *	-	Yield 2025	-

08-25	Senhwa Biosciences Completes Enrollment in Phase 1B Cx-5461 Expansion Trial	CI
08-13	Senhwa Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-12	Senhwa Biosciences Announces Research Advance Involving Investigational Drug Pidnarulex (CX-5461)	CI
08-06	Senhwa Biosciences Receives TFDA Clearance For Multicenter Phase 1b/2a Clinical Trial Of CX-5461 In Combination With PD-1 Inhibitor	CI
05-12	Senhwa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-05	Senhwa Biosciences, Inc. Launches Global Multi-Center Clinical Trial for Cx-5461 and Tislelizumab Combination	CI
04-14	Senhwa Biosciences and Gem Yield Bahamas Limited Sign Memorandum of Understanding for Up to TWD 500 Million Strategic Funding	CI
04-14	Senhwa Biosciences, Inc. announced that it expects to receive TWD 500 million in funding from Global Emerging Markets	CI
03-17	Senhwa Biosciences Inc Demonstrates Breakthrough For CX-5461 In Photodynamic Therapy	CI
03-11	Senhwa Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-03	Senhwa Biosciences And CellType Sign Strategic Memorandum of Understanding to Accelerate Evolution Of CX-4945 Into Version 2.0	CI
12-28	Senhwa Biosciences, Inc. Aims At Multi-Billion Dollar Global Market with CX-5461 Combined with ADC "Blockbuster" Therapy	CI
12-28	Senhwa?s CX-5461 with Astrazeneca/Daiichi Sankyo?s ADC, Trastuzumab Deruxtecan in Phase 1b HER2+ and Breast Cancer Trial; NCI Submits FDA Application	CI

07-15	GEM and Senhwa Biosciences have formally executed a Share Purchase Agreement for up to NT$500 million	AQ
25-07-16	Senhwa Biosciences announces first patient dosed in NCI-sponsored pilot study of Pidnarulex (CX-5461) pharmacodynamics in patients with advanced solid tumors	AQ
24-11-04	Senhwa Biosciences Announces the Appointment of Dr. Yiu-Lian Fong, the Former Global Head of Janssen Diagnostic Innovation and R&D at Johnson & Johnson as the New Corporate Director	AQ
24-10-15	Senhwa Biosciences - US FDA issues Study May Proceed letter for the Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors, Sponsored by the US National Cancer Institute	AQ
24-09-18	Senhwa Biosciences Announces IND Submission to US FDA for Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors sponsored by NCI	AQ

Senhwa Biosciences, Inc. Stock

Stocks

6492

TW0006492002

Biotechnology & Medical Research

Valuation: Senhwa Biosciences, Inc.

Chart: Senhwa Biosciences, Inc.

Latest news: Senhwa Biosciences, Inc.

Press Releases: Senhwa Biosciences, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Senhwa Biosciences, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

1 day	-2.52%
1 week	-4.77%
Current month	-9.90%
1 month	-9.90%
3 months	-20.64%
6 months	-37.98%
Current year	-29.66%

1 week	30.2	32.5
1 month	30.2	34.9
Current year	30.2	66.5
1 year	30.2	66.5
3 years	28.45	66.5
5 years	28.45	134
10 years	28.45	309.5

Manager	Title	Age	Since
Tai Sen Soong CEO	Chief Executive Officer	-	2012-11-15
Hsiao Ping Chang DFI	Director of Finance/CFO	-	2012-12-31
Jason Huang CTO	Chief Tech/Sci/R&D Officer	-	2024-06-02

Director	Title	Age	Since
Ting Wu Hu CHM	Chairman	77	2012-10-31
Tai Sen Soong BRD	Director/Board Member	-	2012-11-15
Hung Min Hsieh BRD	Director/Board Member	-	2012-11-15

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SENHWA BIOSCIENCES, INC.	-2.52%	-4.77%	-31.53%	-43.21%	84.78M
WUXI APPTEC CO., LTD.	-0.62%	-1.87%	+46.31%	+56.99%	63.77B
ARGENX SE	+0.35%	+3.20%	+14.92%	+84.55%	56.37B
LONZA GROUP AG	+0.53%	+1.96%	+15.37%	+106.81%	54.62B
IQVIA HOLDINGS INC.	-2.81%	-4.31%	+23.50%	+50.90%	44.06B
BEONE MEDICINES AG	-0.33%	-1.93%	+20.15%	+98.45%	42.11B
REVOLUTION MEDICINES, INC.	+0.55%	+2.31%	+224.97%	+942.56%	41B
GENMAB A/S	+3.27%	+47.96%	+112.67%	+96.48%	34.92B
CELLTRION, INC.	+1.22%	-1.44%	+14.89%	+47.15%	32.82B
INSMED INCORPORATED	+0.89%	+20.55%	-42.03%	+373.03%	24.7B
Average	+0.05%	+6.31%	+39.92%	+181.37%	39.44B
Weighted average by Cap.	+0.18%	+5.44%	+48.48%	+186.08%

	2024	2025
Net sales	1M 30.67K 27.45K 25.27K 22.87K 42.8K 2.91M 43.64K 301K 120K 1.53M 115K 113K 4.83M	1.07M 32.82K 29.37K 27.04K 24.47K 45.8K 3.12M 46.69K 322K 129K 1.64M 123K 121K 5.17M
Net income	-294M -9.01M -8.06M -7.42M -6.72M -12.57M -855M -12.82M -88.4M -35.38M -449M -33.81M -33.09M -1.42B	-265M -8.12M -7.27M -6.69M -6.06M -11.33M -771M -11.55M -79.68M -31.89M -405M -30.47M -29.82M -1.28B
Net Debt	-1.01B -31.01M -27.75M -25.55M -23.12M -43.27M -2.94B -44.12M -304M -122M -1.55B -116M -114M -4.88B	-750M -22.99M -20.58M -18.95M -17.15M -32.09M -2.18B -32.71M -226M -90.3M -1.15B -86.28M -84.44M -3.62B